The Tumor Immunoenvironment

ISBN-13: 9789402401486 / Angielski / Miękka / 2016 / 745 str.

Michael R. Shurin; Viktor Umansky; Anatoli Malyguine

Opis

This book examines immune cell functioning in cancer, with a focus on both experimental animal results and human clinical trials.

Spis treści

Preface  Dmitry I. Gabrilovich 

Introduction

Role of the immunological environment in cancer initiation, development and progression
Anatoli Malyguine, Viktor Umansky and Michael R. Shurin 

Part I   Tumor Microenvironment and Immunoenvironment

The metastatic microenvironment
Shelly Maman and Isaac P. Witz 

Tumor infiltration by immune cells: pathologic evaluation and a clinical significance
Dmitri W. Gutkin

Immunologic interpretation of cancer biology: impact on clinical outcome
Maria Libera Ascierto, Ena Wang and Francesco M Marincola                       

Part II  Developmental Characteristics of the Tumor ImmunoEnvironment  

Development of antitumor cellular immunity
M.J.P. Welters and S.H. van der Burg  

The versatile world of inflammatory chemokines in cancer
Tal Leibovich-Rivkin, Yaeli Lebel-Haziv, Shalom Lerrer, Polina Weitzenfeld and Adit Ben-Baruch 

Inflammation, Tumor Progression, and Immune Suppression
Suzanne Ostrand-Rosenberg 

Pleiotropic and differential functions of IL-1a and IL-1b shape the tumor microenvironment and affect the outcome of malignancies
Ron N. Apte and Elena Voronov

Impact of obesity and aging on the tumor immunoenvironment
Annie Mirsoian, Gail D. Sckisel, Anthony E. Zamora and William J. Murphy 

Part III Tumor Escape from Immune Recognition 

MHC class I antigens and the tumor microenvironment
Natalia Apsirauri, Teresa Cabrera, Angel Garcia-Lora, Francisco Ruiz-Cabello and Federico Garrido 

Tumor-produced immune regulating factors
Mads Hald Andersen, Jürgen C. Becker and Per thor Straten

Roles of signaling pathways in cancer cells and immune cells in generation of immunosuppressive tumor-associated microenvironmentsYutaka Kawakami, Tomonori Yaguchi, Hidetoshi Sumimoto, Chie Kudo-Saito, Nobuo Tsukamoto, Tomoko Iwata-Kajihara, Shoko Nakamura, Hiroshi Nishio, Ryosuke Satomi, Asuka Kobayashi, Mayuri Tanaka, Jeong Hoon Park, Hajime Kamijuku, Takahiro Tsujikawa and Naoshi Kawamura 

T cell malfunction in the tumor environment
Eitan Yefenof

Signaling of tumor-induced immunosuppression of dendritic cells
Yong Lu, Jing Yang and Qing Yi 

Tumor microenvironment may shape the function and phenotype of NK cells through the induction of split anergy and generation of regulatory NK cells
Anahid Jewett and Han-Ching Tseng           

Part IV  Immune Regulators in the Tumor ImmunoEnvironment 

The role of myeloid-derived suppressor cells in cancer
Jonathan Weiss   

Macrophage differentiation and activation states in the tumor microenvironment
Jo A. Van Ginderachter  

Dendritic cells and cancer: development, dysfunction and therapeutic targets
Stephanie K. Watkins and Arthur A. Hurwitz           

The role of tumor-associated neutrophils in cancer
Zvi G. Fridlender 

Mast cell modulation of the tumor microenvironment
Jean Marshall and Sharon Oldford

Regulatory T cells in patients with cancer
Theresa Whiteside

Tumor-evoked regulatory B cells as important mediators of cancer escape
Catalina Lee-Chang, Monica Bodogai and Arya Biragyn

Part V  Tumor Escape and Cancer Immunotherapy  

Cancer immunotherapy: Overview in brief
Philipp Beckhove 

Programming of MDSC: New opportunities for targeted therapy
Peter Svider, Shu-Hsia Chen and Andy Sikora

Therapeutic targeting regulatory T cells in tumor
Wei Wang and Weiping Zou

ChemoImmunoModulation: Focus on myeloid regulatory cells
Viktor Umansky and Michael R. Shurin 

Combining vaccines with therapies that render tumor cells more susceptible to immune mediated killing
Nishith Singh, James Hodge, Ravi Madan and James L. Gulley

Prophylactic Cancer Vaccines
Pamela L. Beatty and Olivera Finn 

Part VI  Analyzing Immune Responses in Cancer 

Approaches to Immunologic Monitoring of Clinical Trials
Lisa H. Butterfield, Lazar Vujanovic and Angela Pardee  

Evaluation of the tumor immunoenvironment in clinical trials
Anatoli Malyguine, Kimberly Dunham, Thomas Sayers and Michael R. Shurin 

Analysis of Myeloid-derived Suppressor Cells in Patients with Cancer
Peiyuan Zhu, Yevgeniya V. Segal, Galina V. Shurin and Michael R. Shurin

When results of T cell immune monitoring match or do not match clinical   outcomes of tumor vaccine trials - what more could and should we measure?
Paul V. Lehmann and Srividya Sundararaman

 

Blurb

Interaction between malignant cells and their surrounding tissue plays a crucial role in tumor growth, invasiveness and spreading to the distant organs. New findings provide evidence of a principal importance of the immune cells for controlling this interaction and orchestrating multiple events in the tumor microenvironment. The balance between immune cells that support tumor progression and immune cells that sustain tumor-controlling immune surveillance is tightly regulated by various factors originated from both the malignant and non-cancerous cells in the tumor microenvironment. Analysis of multidirectional immunological responses at the tumor site allows forming a new concept of The Tumor ImmunoEnvironment, which is introduced and discussed in the present book with a particular focus on the role of immune cells in controlling the tumor microenvironment at different stages of cancer development. The main goal of this publication is to provide an overview of the current knowledge on the complex and unique role of the immune system, tumor-associated inflammation and tumor-mediated immunomodulation in cancer progression in a way that allows understanding the logistics of cellular and molecular interactions in the tumor lesions. Moreover, it is discussed how these interactions evolve during cancer progression and in response to different kinds of anticancer therapy. It is anticipated that the book will attract many researchers and clinicians in the field of basic and applied tumor immunobiology and open new opportunities for collaborative programs aiming at the development of effective and feasible therapeutic approaches to cancer treatment.